Market Overview

Stifel Cuts NewLink Valuation Estimate In Half On Regulatory, Development Risks

Share:
Stifel Cuts NewLink Valuation Estimate In Half On Regulatory, Development Risks

Despite exceeding bottom-line expectations, NewLink Genetics Corp (NASDAQ: NLNK) plummeted Wednesday on second-quarter sales that were nearly 50 percent below projections. 

Stifel Nicolaus sees little visibility for NewLink going forward. 

The Rating

Stifel Nicolaus analyst Stephen Willey downgraded NewLink Genetics from Buy to Hold and halved the price target from $8 to $4.

The Thesis

NewLink's updated clinical development strategy for indoximod and cost-saving organizational restructuring were not enough to allay Willey’s concerns, the analyst said in the downgrade note. (See Willey's track record here.)

“While the limited amount of indoximod data generated to date in indications management now intends to pursue ... has been (in our opinion) directionally interesting, we believe the visibility (and longer-term optionality) we now have going forward is increasingly limited." 

Willey sees development, regulatory and commercial risks in NewLink’s approach to address acute myeloid leukemia, the firm’s primary indication. At the same time, the program for pediatric brain tumors, while having posted “directionally positive” early results, is expected to suffer development challenges, he said. 

“We’re generally not fans of downgrading stocks trading at cash — particularly ones with decent visibility into the potential monetization of a fiscal 2019 Ebola-related PRV — but struggle to see how this story resonates with investors over the near-term." 

Price Action

NewLink shares were trading down 16.4 percent to $3.16 at the time of publication Wednesday. 

Related Links:

Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial

Bank Of America Sees NewLink Genetics As 'Undervalued'

Latest Ratings for NLNK

DateFirmActionFromTo
Feb 2019MaintainsNeutralNeutral
Jan 2019DowngradesNeutralUnderperform
Nov 2018MaintainsNeutralNeutral

View More Analyst Ratings for NLNK
View the Latest Analyst Ratings

Posted-In: Stephen Willey Stifel NicolausAnalyst Color Biotech Downgrades Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (NLNK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NFLXNomuraMaintains330.0
NFLXMacquarieDowngrades
PEGIGoldman SachsDowngrades25.0
XHRJefferiesDowngrades
USACStifel NicolausDowngrades18.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Earnings Preview: Treehouse Foods

Sally Beauty Q3 Earnings Preview